252 related articles for article (PubMed ID: 30261581)
1. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
3. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
4. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
5. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
[TBL] [Abstract][Full Text] [Related]
6. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
8. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
9. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
[TBL] [Abstract][Full Text] [Related]
10. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
12. Application of digital infrared thermal imaging in determining inflammatory state and follow-up effect of methylprednisolone pulse therapy in patients with Graves' ophthalmopathy.
Chang TC; Hsiao YL; Liao SL
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):45-9. PubMed ID: 17653750
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Gao G; Dai J; Qian Y; Ma F
Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
Pelewicz K; Miśkiewicz P
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38310626
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
Pelewicz K; Szewczyk S; Miśkiewicz P
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
[TBL] [Abstract][Full Text] [Related]
16. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
Bartalena L
Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
19. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
